12.03.2024, 16:02

SPH Incoming transfer from capital increase subject to exercise of warrants from issue BG9200001212

Incoming transfer from capital increase subject to exercise of warrants from issue BG9200001212

Data	Tytuł	Kurs	Zmiana
2024-04-25	SPH Publication of Annual consolidated audited financial report of "Sopharma" AD for 2023 in ESF format	13,05	0,00
2024-04-22	SPH Sales revenues of Sopharma AD for March 2024	13,70	0,00
2024-04-01	SPH Presentation of the Annual Audited Individual Financial Statements of “Sopharma” AD as at 31 December 2022	13,40	0,00
2024-03-20	SPH Sales revenues for February 2024	14,40	-3,13
2024-03-12	SPH Incoming transfer from capital increase subject to exercise of warrants from issue BG9200001212	14,00	-1,43
2024-03-11	SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 08 March 2024 on the acquisition of shares from a capital increase	13,80	+1,45
2024-02-29	SPH Consolidated financial report as of 31 December 2023	13,70	-2,19
2024-02-27	SPH Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212	13,40	+2,99
2024-02-22	SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the acquisition of shares from a temporary issue/exercise of warrants	13,75	-0,73
2024-02-22	SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the exercise of warrants in a capital increase under the condition	13,75	-0,73